Urogen Pharma (NASDAQ:URGN) Stock Price Target Lowered at Guggenheim

Urogen Pharma (NASDAQ:URGN) had its price target trimmed by Guggenheim from $58.00 to $56.00 in a report released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on the company. Oppenheimer set a $60.00 price objective on Urogen Pharma in a report on Thursday. TD Cowen boosted their target price on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. UBS Group reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a research report on Thursday, September 10th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $44.00 price target on shares of Urogen Pharma in a report on Wednesday, July 15th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.38.

Urogen Pharma Trading Down 10.5%

Shares of URGN opened at $25.73 on Thursday. The stock has a market cap of $1.26 billion, a PE ratio of -19.49 and a beta of 1.68. Urogen Pharma has a 1 year low of $16.50 and a 1 year high of $50.81. The stock has a 50 day simple moving average of $39.20 and a 200-day simple moving average of $31.50.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million during the quarter, compared to analyst estimates of $89.92 million. On average, sell-side analysts forecast that Urogen Pharma will post -0.20 EPS for the current fiscal year.

Insider Transactions at Urogen Pharma

In related news, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the transaction, the general counsel directly owned 53,141 shares of the company’s stock, valued at $2,260,618.14. The trade was a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the transaction, the insider owned 59,882 shares in the company, valued at approximately $2,570,135.44. This trade represents a 1.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 65,269 shares of company stock worth $3,037,646. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Urogen Pharma in the 2nd quarter worth approximately $117,814,000. Jefferies Financial Group Inc. bought a new position in Urogen Pharma in the 2nd quarter valued at $80,947,000. Bank of America Corp DE bought a new position in Urogen Pharma in the 2nd quarter valued at $17,506,000. Rice Hall James & Associates LLC acquired a new stake in shares of Urogen Pharma in the 2nd quarter valued at $11,064,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Urogen Pharma in the 2nd quarter valued at $9,288,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Key Headlines Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% from the prior quarter. UroGen also said repeat prescribers accounted for a growing share of ZUSDURI writers. UroGen third-quarter results
• Positive Sentiment: The FDA accepted UroGen’s UGN-103 application for review and set a June 14, 2027 target decision date, providing a potential future catalyst. The company also reported that the first patient was dosed in its UGN-501 Phase 1 trial. UroGen third-quarter results
• Neutral Sentiment: Guggenheim lowered its price target to $56 from $58 but maintained a Buy rating, signaling continued optimism despite the reduced target. Guggenheim rating
• Negative Sentiment: Investors focused on UroGen’s reduced FY2026 guidance and quarterly results that fell short of analyst expectations: reported EPS was a loss of $0.03 versus the cited consensus estimate of $0.11, while revenue of $89 million was slightly below estimates. UroGen Q3 results and guidance

About Urogen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.